FDA Commissioner Marty Makary Resigns After Trump Pressure

Follow Drugslib on

By Andria Park Huynh HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 13, 2026.

via HealthDay

WEDNESDAY, May 13, 2026 — After months of pressure from the Trump administration, U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary has quit.

President Donald Trump posted the news on Truth Social, including the resignation text message he received from Makary.

In the text, Makary highlighted accomplishments during his tenure. He cited speedier drug review; new guidance to advance psychedelics; a new "plausible mechanism pathway" to speed approval of rare disease drugs; and new labeling "to tell women the truth" about menopausal hormone replacements, according to StatNews.

Makary, who was a surgical oncologist and professor at Johns Hopkins University School of Medicine prior to joining the FDA, led the FDA for a little over a year.

“It’s been the honor of a lifetime to serve as your FDA Commissioner,” Makary said in his text to the president. “I am forever grateful.”

The decision comes after Trump signed off last week on a plan to fire him, a move rumored to be in the works since at least late 2025, according to StatNews.

“He’s going to go on and he’s going to lead a good life,” Trump said of Makary. “He was having some difficulty. He’s a great doctor. He’s going to go on and do well. Everybody wants that job.”

As FDA chief, Makary came under fire, particularly over his pushback on approving sale of flavored e-cigarettes. He also angered some Republican lawmakers and the anti-abortion community by "slow-walking" a safety study on the abortion pill mifepristone, according to StatNews.

While Makary was reported to have many ideas to improve FDA regulation, many felt he was ill-suited for the job.

“He was creative and ambitious with ideas to speed up drug development,” said Dr. Roderick Wong, managing partner of biotech hedge fund RTW Investments.

Ultimately, Wong said, Makary was accountable for Dr. Vinay Prasad’s "poor" leadership of the Center for Biologics Evaluation and Research in 2025 and 2026 and his inability to keep someone to head the Center for Drug Evaluation and Research.

In Makary's place, Kyle Diamantas, the FDA’s top food regulator, will step in as acting commissioner during the search for a permanent replacement.

While FDA commissioners typically have medical training and experience, Diamantas does not, making him an unusual choice for the role.

“Kyle Diamantas now has a nearly impossible charge — leading, as a non-scientist, a science-based agency under an unqualified secretary who puts his own medical and nutritional pet peeves over evidence-based public health,” said Peter Lurie, director of the Center for Science in the Public Interest.

It’s unclear how long Diamantas will lead the FDA.

SOURCE: StatNews, May 12, 2026

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-14 02:49

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords